PIRS - Dosing underway in Pieris Pharma's early-stage study of cancer candidate PRS-343; shares up 3% September, 04 2018 01:03 PM Pieris Pharmaceuticals Inc. The first patient has been dosed in a Phase 1 dose-escalation study evaluating Pieris Pharmaceuticals' (PIRS +2.9%) PRS-343, combined with Roche's Tecentriq (atezolizumab), in patients with advanced/metastatic HER2-positive solid tumors. More news on: Pieris Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...